Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.83Piramal Pharma Ltd, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency and growth, with notable increases in operating profit, EPS, asset growth, and net income. Profitability is reasonable, driven by solid returns on capital employed, equity, and assets. However, liquidity appears to be a significant area of concern, and efficiency ratios indicate potential challenges in asset utilization. Financial ratios also reflect some weaknesses, particularly in earnings per share and book value. While coverage ratios are average, the company's growth prospects and profitability offer a positive outlook, but these are counterbalanced by liquidity and efficiency issues. Overall, Piramal Pharma presents a blend of strengths and weaknesses that warrants careful monitoring.
Health Score : 5.83Piramal Pharma Ltd, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency and growth, with notable increases in operating profit, EPS, asset growth, and net income. Profitability is reasonable, driven by solid returns on capital employed, equity, and assets. However, liquidity appears to be a significant area of concern, and efficiency ratios indicate potential challenges in asset utilization. Financial ratios also reflect some weaknesses, particularly in earnings per share and book value. While coverage ratios are average, the company's growth prospects and profitability offer a positive outlook, but these are counterbalanced by liquidity and efficiency issues. Overall, Piramal Pharma presents a blend of strengths and weaknesses that warrants careful monitoring.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
40.46
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-87.02
P/B RATIO
3.47
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.20
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
31.74
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹213.2 as on Sep 1, 2026.
Growth Score : 8.00Growth ratios suggest strong positive momentum, particularly in operating profit, EPS, asset growth, and net income. However, this is counterbalanced by Revenue growth rate. This indicates strong potential for future expansion and profitability. Strategic investments and market positioning may further enhance growth prospects.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 3.86 | 7.97 | 15.38 | 11.99 | -3.08 |
| Operating Profit Growth Rate | -33.47 | -33.79 | 90.3 | 20.72 | -36.19 |
| Earnings Per Share (EPS) Growth | 109.22 | 430.77 | -455.07 | ||
| Asset Growth Rate | 18.06 | 13.47 | 5.45 | 2.29 | 16.44 |
| Net Income Growth Rate | -54.97 | -149.47 | 109.68 | 405.56 | -458.24 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | JBCHEPHARM | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | GLAND | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | NEULANDLAB | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | GRANULES | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | AJANTPHARM | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | APLLTD | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | EMCURE | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | SYNGENE | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 9 | ERIS | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | IPCALAB | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 11 | PPLPHARMA | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 12 | JUBLPHARMA | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | NATCOPHARM | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | WOCKPHARMA | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | PFIZER | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
| 16 | SANOFI | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤28th Apr 26
Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
No Stock News Available at This Moment.
Piramal Pharma Ltd (PPL) is a global pharmaceutical company with a diversified business model. It specializes in Contract Development and Manufacturing Organisation (CDMO), operates in Complex Hospital Generics (CHG), and offers a portfolio of Consumer Healthcare Products (CHP). PPL serves customers worldwide, focusing on specialty and complex products across various therapeutic areas.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Piramal Pharma Ltd's P/E ratio (TTM) is 40.46, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Piramal Pharma Ltd's P/B ratio is 3.47, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Piramal Pharma Ltd's P/S ratio is 3.20, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Piramal Pharma Ltd's PEG ratio is 1.85.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Piramal Pharma Ltd's EV/EBITDA ratio is 31.74.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Piramal Pharma Ltd's ROE is -3.99%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Piramal Pharma Ltd's ROA is 5.13%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Piramal Pharma Ltd's ROCE is 3%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Piramal Pharma Ltd's operating margin is 10.40%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Piramal Pharma Ltd's net margin is -3.68%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Piramal Pharma Ltd's current ratio is 1.45.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Piramal Pharma Ltd's debt-to-equity ratio is 0.54.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Piramal Pharma Ltd's interest coverage ratio is 0.48.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Piramal Pharma Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Piramal Pharma Ltd's EPS is -455.07.
(Source line: "Ratios as of 01 Sept 2026, based on last traded price of ₹213.20. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2022 (as an independent listed entity)
Headquarters: Mumbai, Maharashtra
Core Offerings: Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), Consumer Healthcare Products (CHP)
Stock Listing: NSE (PPLPHARMA), BSE (543635)
Promoter: Piramal Group / Ajay Piramal
The pharmaceutical business was historically a part of Piramal Enterprises Ltd (PEL). In October 2020, the Carlyle Group made a significant investment in the Pharma business. The Board of PEL approved the demerger of the Pharma business in October 2021. The scheme of arrangement became effective on August 19, 2022, leading to the independent listing of Piramal Pharma Ltd on Indian stock exchanges on October 19, 2022.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Contract Development and Manufacturing Organisation (CDMO) | ~59% (FY23) | N/A (segment-wise EBITDA not typically disclosed) |
| Complex Hospital Generics (CHG) | ~25% (FY23) | N/A (segment-wise EBITDA not typically disclosed) |
| Consumer Healthcare Products (CHP) | ~16% (FY23) | N/A (segment-wise EBITDA not typically disclosed) |
Contract Development and Manufacturing Organisation (CDMO): Provides end-to-end drug discovery, development, and manufacturing services for pharmaceutical and biotech companies globally, leveraging a network of integrated facilities.
Complex Hospital Generics (CHG): Focuses on the production and marketing of injectable anesthesia and analgesics, anti-infectives, and other critical care generic products, primarily catering to hospitals in major markets.
Consumer Healthcare Products (CHP): Offers a diverse portfolio of over-the-counter (OTC) products in India across categories like pain relief, skin care, digestion, and vitamins, building strong consumer brands.
Nandini Piramal, Chairperson: Daughter of Ajay Piramal, she provides strategic oversight to the Piramal Group's pharmaceutical and financial services businesses. Peter DeYoung, CEO: An experienced leader with a strong background in the pharmaceutical sector and strategy consulting, he leads Piramal Pharma's global operations and growth strategy.
Piramal Pharma Solutions Private Limited
Piramal Critical Care Inc.
Piramal Pharma Inc.
Piramal Healthcare (UK) Limited
Piramal Critical Care S.A.S. (France)
Piramal Pharma (Pty) Ltd (South Africa)
The most significant recent corporate action was the demerger from Piramal Enterprises Ltd, which resulted in the separate listing of Piramal Pharma Ltd in October 2022. No major recent bonus or rights issues on record since demerger.
The Piramal Pharma Ltd share price today is ₹213.20 on NSE (PPLPHARMA), as of 12 Sept 2026.
As of 01 Sept 2026, Piramal Pharma Ltd share price is ₹213.20, with previous close ₹213.20. Today's range is ₹213.20 to ₹213.20. The 52-week range is ₹213.20 to ₹213.20.
As of today, Piramal Pharma Ltd's market cap is ₹28,355.6 crore (Large Cap).
Piramal Pharma Ltd's current P/E ratio is 40.46, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.
Piramal Pharma Ltd's current P/B ratio is 3.47.
Piramal Pharma Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Piramal Pharma Ltd's EPS (TTM) is ₹-455.07.
Piramal Pharma Ltd (PPL) is a global pharmaceutical company with a diversified business model. It specializes in Contract Development and Manufacturing Organisation (CDMO), operates in Complex Hospital Generics (CHG), and offers a portfolio of Consumer Healthcare Products (CHP). PPL serves customers worldwide, focusing on specialty and complex products across various therapeutic areas.
Piramal Pharma Ltd is promoted by Piramal Group / Ajay Piramal, holding 34.86% as of 01 Sept 2026.
Piramal Pharma Ltd is listed on NSE (PPLPHARMA) and BSE (543635). Its next quarterly results are expected on August 2024 (Q1 FY25).
Return on Assets (ROA)